CU20130139A7 - Derivados glocósidos y usos de los mismos - Google Patents

Derivados glocósidos y usos de los mismos

Info

Publication number
CU20130139A7
CU20130139A7 CU2013000139A CU20130139A CU20130139A7 CU 20130139 A7 CU20130139 A7 CU 20130139A7 CU 2013000139 A CU2013000139 A CU 2013000139A CU 20130139 A CU20130139 A CU 20130139A CU 20130139 A7 CU20130139 A7 CU 20130139A7
Authority
CU
Cuba
Prior art keywords
glocosid
derivatives
same
present
provides
Prior art date
Application number
CU2013000139A
Other languages
English (en)
Inventor
Gregory Raymond Bebernitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46028035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20130139(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20130139A7 publication Critical patent/CU20130139A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El presente invento proporciona un compuesto de la fórmula I un método para fabricar los compuestos del invento, y sus usos terapéuticos. El presente invento además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
CU2013000139A 2011-04-14 2013-10-14 Derivados glocósidos y usos de los mismos CU20130139A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161475476P 2011-04-14 2011-04-14
PCT/IB2012/051799 WO2012140597A1 (en) 2011-04-14 2012-04-12 Glycoside derivatives and their uses for the treatment of diabetes

Publications (1)

Publication Number Publication Date
CU20130139A7 true CU20130139A7 (es) 2014-01-29

Family

ID=46028035

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2013000139A CU20130139A7 (es) 2011-04-14 2013-10-14 Derivados glocósidos y usos de los mismos

Country Status (26)

Country Link
US (2) US8614195B2 (es)
EP (1) EP2697217B1 (es)
JP (1) JP5908973B2 (es)
KR (1) KR20140027250A (es)
CN (1) CN103748090B (es)
AP (1) AP2013007179A0 (es)
AR (1) AR086086A1 (es)
AU (1) AU2012241427B2 (es)
BR (1) BR112013026257A2 (es)
CA (1) CA2832958A1 (es)
CL (1) CL2013002973A1 (es)
CO (1) CO6781541A2 (es)
CR (1) CR20130530A (es)
CU (1) CU20130139A7 (es)
EA (1) EA201391525A1 (es)
ES (1) ES2621007T3 (es)
IL (1) IL228771A0 (es)
MA (1) MA35032B1 (es)
MX (1) MX2013011927A (es)
PE (1) PE20141039A1 (es)
PH (1) PH12013502140A1 (es)
SG (1) SG194463A1 (es)
TN (1) TN2013000413A1 (es)
TW (1) TW201245219A (es)
UY (1) UY34018A (es)
WO (1) WO2012140597A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2719656T3 (es) 2011-06-01 2019-07-11 Green Cross Corp Derivados de difenilmetano novedosos como inhibidores del SGLT2
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
CN105518014B (zh) * 2013-09-09 2018-03-23 上海研健新药研发有限公司 C‑芳基葡糖苷衍生物、其制备方法及其在医药上的应用
ES2605886T3 (es) 2013-09-27 2017-03-16 Sunshine Lake Pharma Co., Ltd. Derivados de glucopiranosilo y sus usos en medicina
ES2969764T3 (es) 2013-12-17 2024-05-22 Boehringer Ingelheim Vetmedica Gmbh Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
CN115671290A (zh) 2014-01-23 2023-02-03 勃林格殷格翰动物保健有限公司 犬科动物中代谢紊乱的治疗
WO2015150299A2 (en) * 2014-04-01 2015-10-08 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
WO2016046150A1 (en) 2014-09-25 2016-03-31 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
KR102659761B1 (ko) 2015-08-27 2024-04-24 베링거잉겔하임베트메디카게엠베하 Sglt-2 억제제를 포함하는 액상 약제학적 조성물
CN105294624B (zh) * 2015-11-16 2018-01-12 山东罗欣药业集团股份有限公司 一种达格列净的制备方法
CN108203432B (zh) * 2016-12-20 2021-03-02 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
US10952989B2 (en) 2017-03-03 2021-03-23 Novartis Ag SGLT1/2 inhibitor LIK066 for treating obesity
WO2020242253A1 (ko) * 2019-05-30 2020-12-03 동아에스티 주식회사 Sglt-2 억제제인 신규 엠파글리플로진 유도체
WO2021121270A1 (zh) * 2019-12-19 2021-06-24 上海研健新药研发有限公司 一种SGLTs抑制剂的纯化方法及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
KR100591585B1 (ko) 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
NZ521369A (en) 2000-03-17 2004-07-30 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
SK287811B6 (sk) 2000-09-29 2011-10-04 Kissei Pharmaceutical Co., Ltd Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
ES2363941T3 (es) 2003-03-14 2011-08-19 Astellas Pharma Inc. Derivados de c-glucósido para el tratamiento de diabetes.
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
CA2525764C (en) 2003-05-20 2012-07-17 Novartis Ag N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
WO2005011592A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indazole-o-glucosides
EP1660509B1 (de) 2003-08-26 2009-02-04 Boehringer Ingelheim International GmbH Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
BRPI0508259A (pt) 2004-03-04 2007-07-31 Kissei Pharmaceutical derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
PL381247A1 (pl) 2004-03-04 2007-05-14 Kissei Pharmaceutical Co., Ltd. Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006010557A1 (de) 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7750145B2 (en) 2004-11-18 2010-07-06 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TW201000494A (en) * 2008-02-13 2010-01-01 Sanofi Aventis Novel aromatic fluoroglycoside derivatives, medicaments comprising these compounds and use thereof
WO2010128152A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof

Also Published As

Publication number Publication date
WO2012140597A1 (en) 2012-10-18
CN103748090A (zh) 2014-04-23
ES2621007T3 (es) 2017-06-30
IL228771A0 (en) 2013-12-31
CL2013002973A1 (es) 2014-03-07
AR086086A1 (es) 2013-11-20
AP2013007179A0 (en) 2013-10-31
EA201391525A1 (ru) 2014-02-28
PE20141039A1 (es) 2014-08-30
CR20130530A (es) 2014-02-04
US20120264700A1 (en) 2012-10-18
KR20140027250A (ko) 2014-03-06
CN103748090B (zh) 2016-09-14
CO6781541A2 (es) 2013-10-31
TW201245219A (en) 2012-11-16
MX2013011927A (es) 2013-11-01
CA2832958A1 (en) 2012-10-18
AU2012241427B2 (en) 2014-11-20
MA35032B1 (fr) 2014-04-03
US20130018005A1 (en) 2013-01-17
TN2013000413A1 (en) 2015-03-30
UY34018A (es) 2012-11-30
SG194463A1 (en) 2013-12-30
JP2014511874A (ja) 2014-05-19
EP2697217B1 (en) 2016-12-28
US8614195B2 (en) 2013-12-24
JP5908973B2 (ja) 2016-04-26
BR112013026257A2 (pt) 2019-09-24
PH12013502140A1 (en) 2017-10-25
AU2012241427A1 (en) 2013-10-31
EP2697217A1 (en) 2014-02-19

Similar Documents

Publication Publication Date Title
CU20130139A7 (es) Derivados glocósidos y usos de los mismos
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CR20140032A (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a
CO6470898A2 (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
CR20140508A (es) Moduladores de la ruta del complemento y usos de los mismos
CU20130094A7 (es) Moduladores de la vía del complemento
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
UY33075A (es) Derivados de ciclohexano y usos de los mismos
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
CR20150371A (es) Inhibidores de prmt5 y sus usos
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
UY35325A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
UY35211A (es) Compuestos tricíclicos
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1
UY33348A (es) Compuestos de furopiridina y usos de los mismos
CL2020001277A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
GT201400042A (es) Compuesto de benzotiazolona
AR132461A2 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY33857A (es) Compuestos de tiofeno 2,3,5-trisustituidos y usos de los mismos.
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos
CO7141426A2 (es) Moduladores de la ruta del complemento y usos de los mismos
CU20140127A7 (es) Moduladores de la ruta del complemento y usos de los mismos
CU20140007A7 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido- pirimidina y su uso como moduladores de receptores de c5a